NYSE:ABT

Abbott Laboratories Competitors

$120.98
-0.11 (-0.09 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$120.40
$121.42
50-Day Range
$105.79
$121.09
52-Week Range
$98.67
$128.54
Volume4.68 million shs
Average Volume4.50 million shs
Market Capitalization$214.96 billion
P/E Ratio34.08
Dividend Yield1.49%
Beta0.68

Abbott Laboratories (NYSE:ABT) Vs. MDT, ISRG, SYK, BDX, EW, and BSX

Should you be buying ABT stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Abbott Laboratories, including Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), and Boston Scientific (BSX).

Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

79.5% of Medtronic shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Medtronic has increased its dividend for 44 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Medtronic and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic041802.82
Abbott Laboratories121302.75

Medtronic presently has a consensus target price of $135.1364, indicating a potential upside of 2.91%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Abbott Laboratories' higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Medtronic.

Profitability

This table compares Medtronic and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic11.98%11.82%6.32%
Abbott Laboratories15.85%27.00%12.39%

Volatility and Risk

Medtronic has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Medtronic and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$30.12 billion5.86$3.61 billionN/AN/A
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15

Abbott Laboratories has higher revenue and earnings than Medtronic.

Summary

Abbott Laboratories beats Medtronic on 9 of the 16 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

83.7% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 0.9% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Intuitive Surgical and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical09902.50
Abbott Laboratories121302.75

Intuitive Surgical presently has a consensus target price of $939.3529, indicating a potential downside of 5.26%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical31.43%16.18%14.23%
Abbott Laboratories15.85%27.00%12.39%

Volatility and Risk

Intuitive Surgical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and Abbott Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.36 billion27.01$1.06 billion$8.82112.41
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Stryker and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker181502.58
Abbott Laboratories121302.75

Stryker presently has a consensus target price of $280.8696, indicating a potential upside of 3.66%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Stryker's higher probable upside, equities analysts plainly believe Stryker is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 6.7% of Stryker shares are owned by company insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Stryker and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.35 billion7.12$1.60 billion$7.4336.47
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.82%26.08%10.41%
Abbott Laboratories15.85%27.00%12.39%

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Stryker pays out 33.9% of its earnings in the form of a dividend. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility and Risk

Stryker has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Becton, Dickinson and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Becton, Dickinson and05402.44

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Becton, Dickinson and has a consensus price target of $276.75, indicating a potential upside of 8.21%. Given Becton, Dickinson and's higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are held by institutional investors. Comparatively, 83.3% of Becton, Dickinson and shares are held by institutional investors. 1.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Abbott Laboratories and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15
Becton, Dickinson and$17.12 billion4.35$874 million$10.2025.07

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories15.85%27.00%12.39%
Becton, Dickinson and8.98%15.53%6.94%

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has raised its dividend for 49 consecutive years and Becton, Dickinson and has raised its dividend for 50 consecutive years.

Risk and Volatility

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Edwards Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Edwards Lifesciences151202.61

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Edwards Lifesciences has a consensus price target of $117.9333, indicating a potential upside of 5.04%. Given Edwards Lifesciences' higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 80.3% of Edwards Lifesciences shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15
Edwards Lifesciences$4.39 billion15.91$823.40 million$1.8660.36

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories15.85%27.00%12.39%
Edwards Lifesciences29.69%30.81%19.49%

Volatility & Risk

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Abbott Laboratories and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15
Boston Scientific$9.91 billion6.54$-82,000,000.00$0.9647.50

Abbott Laboratories has higher revenue and earnings than Boston Scientific. Abbott Laboratories is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Boston Scientific031112.87

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Boston Scientific has a consensus price target of $48.91, indicating a potential upside of 7.26%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories15.85%27.00%12.39%
Boston Scientific4.56%12.76%6.43%

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 89.6% of Boston Scientific shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Boston Scientific on 8 of the 15 factors compared between the two stocks.


Abbott Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.5$131.31-0.5%$175.62 billion$30.12 billion49.36Short Interest Increase
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$991.46-1.0%$116.55 billion$4.36 billion74.10Insider Selling
Stryker logo
SYK
Stryker
2.1$270.94-0.6%$101.51 billion$14.35 billion49.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.2$255.75-0.2%$74.25 billion$17.12 billion45.51Upcoming Earnings
Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$112.27-0.6%$69.39 billion$4.39 billion48.18Earnings Announcement
Analyst Report
Short Interest Increase
News Coverage
Boston Scientific logo
BSX
Boston Scientific
1.9$45.60-0.6%$64.40 billion$9.91 billion138.19Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.6$678.53-3.8%$60.05 billion$2.71 billion87.33Earnings Announcement
News Coverage
Gap Down
High Trading Volume
DexCom logo
DXCM
DexCom
2.0$515.51-11.5%$44.10 billion$1.93 billion98.19Earnings Announcement
Analyst Report
Insider Selling
News Coverage
Gap Up
High Trading Volume
High Trading Volume
ResMed logo
RMD
ResMed
1.8$271.80-0.8%$39.25 billion$2.96 billion86.84Upcoming Earnings
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Baxter International logo
BAX
Baxter International
2.4$77.35-0.0%$38.91 billion$11.67 billion35.32Earnings Announcement
Analyst Report
News Coverage
High Trading Volume
High Trading Volume
Hologic logo
HOLX
Hologic
1.9$75.04-1.6%$18.71 billion$3.78 billion9.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
STERIS logo
STE
STERIS
2.1$217.95-0.5%$18.51 billion$3.11 billion47.28
Teleflex logo
TFX
Teleflex
2.2$397.43-0.4%$18.51 billion$2.54 billion53.63Earnings Announcement
Dividend Announcement
Analyst Report
Short Interest Increase
News Coverage
Insulet logo
PODD
Insulet
1.5$279.69-2.1%$18.14 billion$904.40 million2,151.46Upcoming Earnings
Masimo logo
MASI
Masimo
1.7$272.39-0.2%$15.02 billion$1.14 billion70.57Earnings Announcement
Analyst Report
Analyst Revision
Abiomed logo
ABMD
Abiomed
1.6$327.14-0.7%$14.73 billion$847.52 million66.36Upcoming Earnings
News Coverage
Hill-Rom logo
HRC
Hill-Rom
1.7$138.46-1.2%$9.10 billion$2.88 billion32.89Earnings Announcement
Insider Selling
Unusual Options Activity
News Coverage
High Trading Volume
High Trading Volume
Globus Medical logo
GMED
Globus Medical
1.9$83.17-0.3%$8.37 billion$789.04 million69.89Upcoming Earnings
News Coverage
Integra LifeSciences logo
IART
Integra LifeSciences
1.6$72.39-1.8%$6.01 billion$1.37 billion30.04Earnings Announcement
Analyst Revision
News Coverage
AtriCure logo
ATRC
AtriCure
1.5$84.46-1.0%$3.82 billion$206.53 million-76.09Upcoming Earnings
Insider Selling
Integer logo
ITGR
Integer
1.6$97.89-1.8%$3.29 billion$1.07 billion33.41Earnings Announcement
Analyst Report
News Coverage
NuVasive logo
NUVA
NuVasive
1.3$63.95-1.4%$3.26 billion$1.05 billion3,199.10Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Cardiovascular Systems logo
CSII
Cardiovascular Systems
2.0$40.29-1.3%$1.64 billion$236.54 million-63.95Upcoming Earnings
Short Interest Increase
Alphatec logo
ATEC
Alphatec
2.2$14.74-0.6%$1.43 billion$144.86 million-13.40Upcoming Earnings
CryoLife logo
CRY
CryoLife
1.6$27.00-1.5%$1.07 billion$253.23 million-87.09Earnings Announcement
Analyst Report
News Coverage
High Trading Volume
High Trading Volume
AngioDynamics logo
ANGO
AngioDynamics
1.8$26.63-0.5%$1.02 billion$291.01 million-32.48
Surmodics logo
SRDX
Surmodics
1.9$55.11-0.5%$768.43 million$94.86 million105.98Upcoming Earnings
Orthofix Medical logo
OFIX
Orthofix Medical
1.5$39.74-1.5%$765.53 million$406.56 million-26.49Upcoming Earnings
Short Interest Increase
News Coverage
Accuray logo
ARAY
Accuray
2.1$4.10-1.0%$386.10 million$382.93 million102.53
Invacare logo
IVC
Invacare
0.9$7.23-1.5%$248.88 million$850.69 million-5.78Upcoming Earnings
Rockwell Medical logo
RMTI
Rockwell Medical
1.6$0.73-1.4%$69.54 million$62.20 million-1.97Gap Down
This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.